Since the first stem cell transplant occurred more than 65 years ago (1957), there has been a nearly exponential increase in stem cell transplants, and in late 2012, the millionth stem cell transplant occurred, a landmark event in stem cell medicine. It is clear that the stem cells contained within cord blood banking now have the potential to improve and save lives. Since the first cord blood transplant was performed in 1988, stem cells derived from umbilical blood have been used in more than 40,000 transplants worldwide. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
New Study Reveals Breakthrough in Epidermal Regeneration Using Mesenchymal Stem Cell Extracellular Vesicles and Ronawk’s Bio-Blocks™
Overland Park, KS – In a groundbreaking development, a recent peer-reviewed paper titled “Mesenchymal Stem Cell Extracellular Vesicles from Tissue-Mimetic System Enhance Epidermal Regeneration via Formation of Migratory Cell Sheets,” published on July 29, 2023, in the journal “Tissue Engineering and Regenerative Medicine,” offers open access to its findings. [Read more…]
Neobiosis Announces FDA Approval of IND for Use of ViXomeTM in COVID-19 ‘Post Covid Syndrome’
GAINESVILLE, Fla., – Neobiosis, is a leading research and manufacturing biotechnology company focused on pioneering the development of novel therapeutics from perinatal tissues as a new class of medicines. Today, Neobiosis announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ViXome™, its drug for the treatment of ‘Post COVID Syndrome (AKA “Long Haul COVID Syndrome”). [Read more…]
StemCyte to Supply Raw Materials for Immune Cell Therapies Derived from Umbilical Cord Blood
BALDWIN PARK, Calif., — As international demand for starting substances for use in cell therapy emerges, California-based regenerative therapeutics company StemCyte announced it has signed a cooperation agreement with a leading US cell therapy company that is developing allogeneic genetically modified CAR-NK cells using umbilical cord blood. StemCyte has agreed to supply the necessary cellular raw materials for allogeneic cell therapy product development worldwide. [Read more…]
IPS HEART Advances Development of ISX9-CPC, a Drug Candidate that Reprograms iPSCs into New, Functional Heart Muscle
HOUSTON–IPS HEART, a privately held cell therapy company advancing its stem cell platform to develop new skeletal muscle and cardiac muscle generation treatments for Duchenne muscular dystrophy (a rare disease) and heart failure, today announced that the U.S. Food and Drug Administration (FDA) awarded a third Rare Pediatric Drug Designation (RPDD) for its product candidate, ISX9-CPC, for treatment of cardiomyopathy associated with Danon disease. ISX9-CPC stem cell therapeutic candidate is designed to create new functional human heart muscle along with reducing cardiac fibrosis. [Read more…]
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 62
- Next Page »